Form 4: Kura Oncology Chief Scientific Officer Sells Shares to Cover Taxes

Kura Oncology's Chief Scientific Officer, Francis Burrows, sold shares to cover taxes related to the vesting of restricted stock units.

Summary

• Francis Burrows, the Chief Scientific Officer of Kura Oncology, sold a total of 2,166 shares of common stock on January 28, 2025.
• The sales were executed at a price of $7.8719 per share.
• 846 shares were sold to cover taxes associated with the vesting of a restricted stock unit (RSU) granted on January 26, 2021.
• 1,320 shares were sold to cover taxes associated with the vesting of an RSU granted on January 26, 2022.
• Following these transactions, Mr. Burrows directly owns 20,705 shares of Kura Oncology common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions and is common for executives who receive stock-based compensation.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations related to vesting of stock awards are a common practice across the industry.
• The number of shares sold and the price are within the typical range for such transactions.
• Similar filings are regularly made by executives at comparable biotech companies.

Stakeholder Impact

• The stock sale by the Chief Scientific Officer may have a minor impact on the share price, but it is not expected to be significant.

Key Dates

Keywords

Kura Oncology, insider trading, Form 4, stock sale, Francis Burrows, restricted stock units, RSU, tax obligations